We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple sclerosis. This short discussion reviews the path to approval, the importance of the first approval for an oral short-course treatment option, and the future holds for this drug.
To learn more about current and future treatment options for MS patients, click here.
Professor Ralf Gold
Global Neurology Academy Steering Committee Member
Professor and Department Chair
St Josef Spital; Ruhr University Bochum
Bochum, Germany
Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple sclerosis. This short discussion reviews the path to approval, the importance of the first approval for an oral short-course treatment option, and the future holds for this drug.
To learn more about current and future treatment options for MS patients, click here.
Professor Ralf Gold
Global Neurology Academy Steering Committee Member
Professor and Department Chair
St Josef Spital; Ruhr University Bochum
Bochum, Germany
Stay current with the best on medical education
